Testing a New Drug for Advanced Colon, Rectal, or Pancreatic Cancer
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug, alone or combined with other treatments, for advanced colon, rectal, or pancreatic cancer that hasn't responded to standard options or cannot be removed by surgery. The goal is to see if it is safe and if it helps shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced colon, rectal, or pancreatic cancer that cannot be surgically removed.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- Your organs (like liver and kidneys) are functioning well enough.
- You have not had certain prior treatments (like an antibody-drug conjugate with a topoisomerase-1 inhibitor).
- You are willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug combined with other treatments for advanced pancreatic cancer. It aims to see if the combination can help people whose cancer has a specific genetic change called RAS mutation.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.